Asset Details
Do you wish to reserve the book?
Immune checkpoint inhibitor-related kelch-like protein 11-IgG cerebellitis successfully treated with efgartigimod as rescue therapy: a case report
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Immune checkpoint inhibitor-related kelch-like protein 11-IgG cerebellitis successfully treated with efgartigimod as rescue therapy: a case report
Do you wish to request the book?
Immune checkpoint inhibitor-related kelch-like protein 11-IgG cerebellitis successfully treated with efgartigimod as rescue therapy: a case report
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Immune checkpoint inhibitor-related kelch-like protein 11-IgG cerebellitis successfully treated with efgartigimod as rescue therapy: a case report
2026
Overview
While immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, neurological immune-related adverse events (n-irAEs) associated with these agents are increasingly recognized. However, kelch-like protein-11(KLHL11)-IgG cerebellitis has not been reported as an n-irAE.
We report a case of a 53-year-old man with lung adenocarcinoma treated with tislelizumab who developed KLHL11-IgG cerebellitis. First-line immunotherapy, comprising intravenous methylprednisolone and immunoglobulin, failed to improved his symptoms. Subsequent administration of efgartigimod (10 mg/kg weekly for 4 doses) led to seroconversion of KLHL11-IgG and marked clinical recovery.
This is the first report of efgartigimod as a successful rescue therapy for isolated ICI-related KLHL11-IgG cerebellitis. These findings support efgartigimod as a promising treatment option for this condition.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Adenocarcinoma of Lung - drug therapy
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Ataxia
/ Blood
/ Cerebellar Diseases - chemically induced
/ Cerebellar Diseases - diagnosis
/ Cerebellar Diseases - drug therapy
/ Cerebellar Diseases - immunology
/ Gait
/ Humans
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - adverse effects
/ Immune Checkpoint Inhibitors - therapeutic use
/ Immunoglobulin G - immunology
/ Kinases
/ Lung Neoplasms - drug therapy
/ Male
/ Patients
/ Proteins
/ Tumors
/ Vomiting
